
Afanat 20 Tablet
Marketer
Natco Pharma Ltd
Salt Composition
Afatinib dimaleate (20mg)
Overview Afanat 20 Tablet
Afana 20mg tablets are indicated for treating non-small cell lung cancer in adults with specific epidermal growth factor receptor (EGFR) gene mutations. Optimal absorption requires administration on an empty stomach, consistently at the same time daily. Dosage and frequency are determined individually by your physician, based on your condition and may vary. Adhere strictly to your prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may not be immediately apparent, potentially requiring weeks or months; discontinue only under medical supervision. Common side effects include nausea, diarrhea (which may necessitate medical intervention or increased hydration), rash, and dry skin. Regular blood monitoring may be advised. Photosensitivity is possible; use sun protection accordingly. Report ocular discomfort (pain, redness, dryness) to your doctor promptly. Prior to commencing treatment, disclose any respiratory, hepatic, or renal issues, and all other medications, particularly those for infections, as interactions are possible. This medication is contraindicated during pregnancy and lactation; effective contraception is essential for women undergoing treatment.
Primary Ingredients of Afanat 20 Tablet
No text provided to rephrase.
Uses of Afanat 20 Tablet
Lung cancer (non-small cell type)
Major Benefits of Afanat 20 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Afanat 20 Tablet whole; avoid chewing, crushing, or breaking it. Administer on an empty stomach.
Common Side effects of Afanat 20 Tablet:
- Diarrhea
- Rash
- Dry skin
- Nausea
- Vomiting
- Loss of appetite
- Itching
- Stomatitis (Inflammation of the mouth)
- Nail disorder
How to use Afanat 20 Tablet:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Afanat 20 Tablets should be taken on an empty stomach.
How Afanat 20 Tablet works:
Afanat 20 Tablet is an anti-neoplastic agent. Its mechanism of action involves targeted inhibition of enzyme receptors—EGFR, HER2, and HER4—crucial for cancer cell proliferation. This blockade consequently suppresses downstream signaling cascades, thereby hindering or retarding tumor growth.
SAFETY ADVICE
AlcoholSAFE
There are no reported adverse interactions between Afanat 20 Tablet and alcohol consumption.
PregnancyCONSULT YOUR DOCTOR
Using Afanat 20 Tablet during pregnancy is strongly discouraged due to documented risks to the fetus. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Afanat 20 Tablet while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Afanat 20 Tablet on driving ability is undetermined. Refrain from operating a vehicle if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Afanat 20 Tablet appears to pose minimal risk for individuals with kidney impairment. Existing evidence indicates dose modification may be unnecessary, but physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Afanat 20 Tablet is likely safe for individuals with hepatic impairment. Existing evidence indicates dose modification may be unnecessary, however, physician consultation is recommended.
What if you forget to take Afanat 20 Tablet :
Omit any missed Afanat 20 Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Afanat 20 Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-Butenamide Hybrid |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Kinase inhibitors targeting tyrosine |
